IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death

Cell Death and Differentiation

Volumn 16, Issue 5, 2009, Pages 708-718

  Czystowska, M ^a   Han, J ^a   Szczepanski, M J ^a   Szajnik, M ^a   Quadrini, K ^b   Brandwein, H ^b   Hadden, J W ^b   Signorelli, K ^b   Whiteside, T L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b IRX Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; CASPASE; FAS LIGAND; IMMUNOMODULATING AGENT; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; IRX 2; JANUS KINASE 3; STAT5 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG EFFICACY; GENE ACTIVATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; JANUS KINASE 3; JURKAT CELLS; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TIME FACTORS;

EID: 67349283470     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2008.197     Document Type: Article

References (34)

1. Whiteside TL. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006; 16: 3-15.
2. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002; 8: 3137-3145.
3. Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002; 8: 2553-2562.
4. Saito T, Kuss I, Dworacki G, Gooding W, Johnson JT, Whiteside TL. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 1999; 5: 1263-1273.
5. Gastman BR, Atarashi Y, Reichert TE, Saito T, Balkir L, Rabinowich H et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999; 59: 5356-5364.
6. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Cancer as a site of immune privilege. Immunol Today 1999; 20: 46-52.
7. Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D et al. FasL:FAs ratio - a prognostic factor in breast carcinomas. Cancer Res 2000; 60: 822-828.
8. Soubrane C, Mouawad R, Antoine EC, Verola O, Gil-Delgado M, Khayat D. A comparative study of Fas and Fas-ligand expression during melanoma progression. Br J Dermatol 2000; 143: 307-312.
9. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 2008; 15: 80-88.
10. Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 2005; 92: 305-311.
11. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 2005; 11: 1010-1020.
12. Hadden J, Verastegui E, Barrera JL, Kurman M, Meneses A, Zinser JW et al. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int Immunopharmacol 2003; 3: 1073-1081.
13. Egan JE, Quadrini KJ, Santiago-Schwarz F, Hadden JW, Brandwein HJ et al. IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro. J Immunother 2007; 30: 624-633.
14. Sabapatha A, Gercel-Taylor C, Taylor DD. Specific isolation of placenta-derived exosomes from the circulation of pregnant women and their immunoregulatory consequences. Am J Reprod Immunol 2006; 56: 345-355.
15. Whiteside TL. Tumour-derived exosomes or microvesicles: Another mechanism of tumour escape from the host immune system? Br J Cancer 2005; 92: 209-211.
16. Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 2007; 67: 2912-2915.
17. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004; 202: 275-293.
18. Meneses A, Verastegui E, Barrera JL, de la Garza J, Hadden JW. Lymph node histology in head and neck cancer: Impact of immunotherapy with IRX-2. Int Immunopharmacol 2003; 3: 1083-1091.
19. Duenas-Gonzalez A, Verastegui E, Lopez-Graniel C, Gonzalez A, Mota A, Barrera-Franco JL et al. A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma. Int Immunopharmacol 2002; 2: 1007-1016.
20. Hadden JW, Verastegui E, Hadden E. IRX-2 and thymosin alpha1 (Zadaxin) increase T lymphocytes in T lymphocytopenic mice and humans. Ann NY Acad Sci 2007; 112: 245-255.
21. Barrera JL, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. Combination immunotherapy of squamous cell carcinoma of the head and neck: A phase 2 trial. Arch Otolaryngol Head Neck Surg 2000; 126: 345-351.
22. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9: 59-71.
23. Wajant H. The Fas signaling pathway: More than a paradigm. Science 2002; 296: 1635-1636.
24. Stepczynska A, Lauber K, Engels IH, Janssen O, Kabelitz D, Wesselborg S et al. Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation. Oncogene 2001; 20: 1193-1202.
25. Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S et al. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 1999; 144: 891-901.
26. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856-859.
27. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
28. Han J, Goldstein LA, Gastman BR, Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 2006; 281: 10153-10163.
29. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003; 426: 671-676.
30. Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007; 18: 171-182.
31. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006; 24: 657-679.
32. Budd RC, Yeh WC, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol 2006; 6: 196-204.
33. Schmitz I, Weyd H, Krueger A, Baumann S, Fas SC, Krammer PH et al. Resistance of short term activated T cells to CD95-mediated apoptosis correlates with de novo protein synthesis of c-FLIPshort. J Immunol 2004; 172: 2194-2200.
34. Ross JA, Nagy ZS, Cheng H, Stepkowski SM, Kirken RA. Regulation of T cell homeostasis by JAKs and STATs. Arch Immunol Ther Exp (Warsz) 2007; 55: 231-245.